- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
BI Announces Positive Phase 3 Results for Its Biosimilar Adalimumab
On Wednesday, Boehringer Ingelheim announced results from a phase 3 trial of its adalimumab biosimilar candidate, BI 695501. The study’s results showed that BI 695501 and AbbVie’s branded adalimumab, Humira, have similar clinical efficacy, safety, and immunogenicity in patients with moderate to severe rheumatoid arthritis.
On Wednesday, Boehringer Ingelheim (BI) announced results from a phase 3 trial of its adalimumab biosimilar candidate, BI 695501. The study’s results showed that BI 695501 and AbbVie’s branded adalimumab, Humira, have similar clinical efficacy, safety, and immunogenicity in patients with moderate to severe rheumatoid arthritis (RA).
In the study, 645 patients, aged 18 to 80, with moderate to severe RA and on stable treatment with methotrexate were assessed. The patients were randomized to receive either the reference adalimumab or the biosimilar product at 40 gm every 2 weeks over a period of 48 weeks.
The study met its 2 primary endpoints, which measured 12- and 24-week ACR20 improvement, or the American College of Rheumatology 20% improvement in tender and swollen joint counts, patient assessments of pain, global disease activity and physical function, physician global assessment of disease activity, and acute phase reactant. Additional data from the study demonstrate pharmacokinetic similarity of the biosimilar’s presentation as either a pre-filled syringe or auto-injector.
Karen Kissel, MD, head of Global Medical Affairs Biosimilars at BI, said, “The result that [BI 695501] delivers the same clinical benefits and safety profile as Humira is great news for patients and physicians. If approved by regulatory authorities, it will increase the treatment options for patients with autoimmune diseases, while contributing to the long-term sustainability of healthcare systems.”
The manufacturer has indicated that 24-week results from the study will be presented at the Annual European Congress of Rheumatology, convened this week in Madrid, Spain; 1-year results will be presented at a future medical congress.
BI’s results only add to AbbVie’s woes; in May, the US Patent Trial and Appeal Board ruled against AbbVie, invalidating a dosing patent for Humira in the treatment of RA. AbbVie, which relies on Humira for 63% of its annual sales (ammounting to $16.08 billion in 2016 alone), continues to hold 3 formulation patents for the drug, but the board’s decision cleared the way for biosimilars manufacturers to move forward with their products. In addition to BI’s biosimilar, AbbVie also faces challenges from Coherus, which is developing a biosimilar adalimumab of its own.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
February 5th 2025Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
